Medpace Holdings Inc (MEDP) Expected to Post Earnings of $0.68 Per Share
Brokerages predict that Medpace Holdings Inc (NASDAQ:MEDP) will report earnings of $0.67 per share for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Medpace’s earnings. The highest EPS estimate is $0.73 and the lowest is $0.64. Medpace reported earnings of $0.39 per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 71.8%. The business is scheduled to issue its next earnings report on Monday, February 25th.
According to Zacks, analysts expect that Medpace will report full-year earnings of $2.51 per share for the current fiscal year, with EPS estimates ranging from $2.47 to $2.56. For the next year, analysts expect that the firm will post earnings of $2.90 per share, with EPS estimates ranging from $2.84 to $2.96. Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that follow Medpace.
Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Thursday, November 1st. The company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.63 by $0.04. Medpace had a net margin of 10.84% and a return on equity of 15.86%. The company had revenue of $179.00 million during the quarter, compared to the consensus estimate of $175.07 million. During the same period in the previous year, the firm earned $0.40 earnings per share. Medpace’s revenue for the quarter was up 44.4% on a year-over-year basis.
MEDP opened at $58.74 on Wednesday. The company has a quick ratio of 0.66, a current ratio of 0.66 and a debt-to-equity ratio of 0.25. Medpace has a 52-week low of $31.70 and a 52-week high of $65.09. The company has a market cap of $2.07 billion, a price-to-earnings ratio of 38.64, a price-to-earnings-growth ratio of 1.46 and a beta of 1.41.
In related news, major shareholder Medpace Limited Partnership sold 5,224,997 shares of the company’s stock in a transaction on Monday, August 27th. The shares were sold at an average price of $54.75, for a total value of $286,068,585.75. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Medpace Investors, Llc sold 61,141 shares of the company’s stock in a transaction on Wednesday, September 19th. The shares were sold at an average price of $60.20, for a total transaction of $3,680,688.20. Following the completion of the sale, the insider now directly owns 9,084,369 shares in the company, valued at $546,879,013.80. The disclosure for this sale can be found here. Insiders sold 5,621,556 shares of company stock worth $309,490,974 over the last ninety days. 29.50% of the stock is currently owned by corporate insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC acquired a new stake in shares of Medpace during the second quarter worth $107,000. Cim LLC acquired a new stake in shares of Medpace during the third quarter worth $218,000. Atria Investments LLC acquired a new stake in shares of Medpace during the third quarter worth $246,000. Metropolitan Life Insurance Co. NY raised its holdings in shares of Medpace by 57.1% during the second quarter. Metropolitan Life Insurance Co. NY now owns 4,144 shares of the company’s stock worth $178,000 after purchasing an additional 1,507 shares during the period. Finally, Sei Investments Co. raised its holdings in shares of Medpace by 5,087.5% during the second quarter. Sei Investments Co. now owns 4,565 shares of the company’s stock worth $196,000 after purchasing an additional 4,477 shares during the period. 40.22% of the stock is currently owned by hedge funds and other institutional investors.
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
Featured Story: Terms to Better Understand Call Options
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.